Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulations of fosaprepitant and aprepitant

A water-based preparation and solid preparation technology, which is applied in the field of fosaprepitant and aprepitant preparations, can solve the problems of treatment refusal and delay

Active Publication Date: 2019-05-21
ZHUHAI BEIHAI BIOTECH CO LTD
View PDF16 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The syndrome has a significant impact on patients' functional status and quality of life, and patients may delay scheduled chemotherapy due to CINV and sometimes even refuse potentially curative treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations of fosaprepitant and aprepitant
  • Formulations of fosaprepitant and aprepitant
  • Formulations of fosaprepitant and aprepitant

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0536] Example 1: Composition comprising Fosaprepitant and Human Serum Albumin (HSA).

[0537] The prepared fosaprepitant dimeglumine and HSA have a weight ratio of about 1:40.

[0538] In a vial, Fosaprepitant dimeglumine (10 mg) was dissolved in water (2 ml) to give a clear solution. A solution of HSA (400 mg, 2 ml) (20% human serum albumin solution for infusion (product name: AlbuRx) from CSLBehring) was added to a vial of fosaprepitant dimeglumine aqueous solution at 0°C . After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0539] A 100 mg lyophilized solid sample was reconstituted by adding 2 mL of water to obtain a clear aqueous solution.

example 2

[0540] Example 2: Composition comprising fosaprepitant and human serum albumin (HSA).

[0541] The prepared fosaprepitant dimeglumine and HSA have a weight ratio of about 1:20.

[0542] In a vial, Fosaprepitant dimeglumine (10 mg) was dissolved in water (1 ml) to give a clear solution. A solution of HSA (200 mg, 1 ml) (20% human serum albumin solution for infusion (product name: AlbuRx) from CSLBehring) was added to a vial of fosaprepitant dimeglumine aqueous solution at 0°C . After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0543] A 100 mg lyophilized solid sample was reconstituted by adding 2 mL of water to obtain a clear aqueous solution.

example 3

[0544] Example 3: Compositions comprising fosaprepitant and human serum albumin (HSA).

[0545] The prepared fosaprepitant dimeglumine and HSA have a weight ratio of about 1:4.

[0546] In a vial, Fosaprepitant dimeglumine (25 mg) was dissolved in water (1.5 ml) to give a clear solution. A solution of HSA (100 mg, 0.5 ml) (20% human serum albumin solution for infusion (product name: AlbuRx) from CSLBehring) was added to a vial of fosaprepitant dimeglumine aqueous solution at 0°C middle. After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0547] A 100 mg lyophilized solid sample was reconstituted by adding 2 mL of water to obtain a clear aqueous solution.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant,or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.

Description

[0001] priority statement [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 370,453, filed August 3, 2016, and U.S. Provisional Application No. 62 / 412,085, filed October 24, 2016. The entire contents of the aforementioned applications are hereby incorporated by reference. technical field [0003] This document relates to compositions and formulations for the treatment and prevention of chemotherapy-induced nausea and vomiting, more particularly to compositions comprising fosaprepitant or a pharmaceutically acceptable salt thereof, compositions comprising aprepitant , and a composition comprising fosaprepitant or a pharmaceutically acceptable salt thereof and aprepitant. Background technique [0004] Nausea and vomiting are common complications of cancer chemotherapy. Patients consistently report that chemotherapy-induced nausea and vomiting (CINV) is the aspect of treatment they find most unpleasant and distressing. The syndrome has a sig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/675A61K31/5377A61K38/38A61K47/42
CPCA61K31/5377A61K45/06A61K47/42A61K9/08A61P1/08A61K2300/00A61K31/675A61K9/0019A61K9/19A61K38/385Y02A50/30
Inventor 孙群
Owner ZHUHAI BEIHAI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com